Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma. Khan AB, English CW, Chen WC, Athukuri P, et al. Acta Neuropathol 2023 Feb 2. doi: 10.1007/s00401-023-02543.

Read + Share

Amedeo Smart

Independent Medical Education

Khan AB, English CW, Chen WC, Athukuri P, et al. Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma. Acta Neuropathol 2023 Feb 2. doi: 10.1007/s00401-023-02543.
PMID: 36729132